Acute Dermal Sensitization Testing

In Vivo & In Vitro Toxicology

MB Research Labs is a leader in the development of alternative & in vitro sensitization test methods.

Skin Sensitization Testing Approaches

What is Acute Dermal Sensitization Testing?

Acute Dermal Sensitization or Allergic Contact Dermatitis (ACD), the clinical manifestation of contact sensitization, can be caused by dermal exposure to pharmaceuticals, industrial chemicals, consumer products and cosmetics. This is a serious health concern to consumers and governmental regulatory agencies alike. Contact dermatitis can cause physical, emotional and occupational issues for those affected, with an estimated annual cost of $1 Billion.

For more information about Sensitization Testing:
US 1-215-536-4110

Or Contact MB.

Sensitization Testing Approaches

In Vitro

In Vivo

What is a Skin Sensitizer?

A skin sensitizer as defined by the Globally Harmonized System for Classification and Labelling of Chemicals (GHS) as "a substance that will lead to an allergic response following skin contact". (UNECE, 2004)

EPA-OCSPP Guidelines:

OCSPP Series 870 (OCSPP Harmonized Guidelines)*

*Formerly known as OPPTS.

Acute Toxicity Guidelines

(Background)

** Link to pdf

Subchronic Toxicity Guidelines

** Link to pdf

Genetic Toxicity Guidelines

  • 870.5100 - Bacterial Reverse Mutation Test (Ames) **

MB Research - In Vitro Sensitization ITS

MB Research has developed a non-animal Integrated Testing Strategy (ITS) for chemical-induced contact hypersensitivity (skin sensitization). This ITS provides a completely non-animal alternative to traditional testing methods. Together, our three assays address three key events on the skin sensitization adverse outcome pathway (AOP).

The In Vitro Sensitization Assay (IVSA) is a keratinocyte activation test. IVSA uses an ELISA method to measure IL-18 release from a topically treated reconstructed 3D human keratinocyte tissue model.

The Human Cell Line Activation Test (h-CLAT) is a dendritic cell activation test. The h-CLAT uses flow cytometry to measure CD86 and CD54 expression on treated THP-1 cells in culture.

The Direct Peptide Reactivity Assay (DPRA) is an in chemico method used to predict epidermal protein binding. Binding of epidermal proteins is the molecular initiating event on the AOP. The DPRA uses HPLC to measure the depletion of synthetic peptides in solution following exposure to test chemicals.

Call for Quote or for more information about your testing needs:
US 1-215-536-4110

Or Contact MB.

Skin Sensitization Adverse Outcome Pathway (AOP)

MB Research proudly serves these industries: